NP cells were then treated with psoralen, exosomes from adipose-derived stem cells overexpressing SPC25 (ADSCs-oe-SPC25-Exos), or a combination of both.
Journal of Orthopaedic Surgery and Research · 7 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
NP cells were then treated with psoralen, exosomes from adipose-derived stem cells overexpressing SPC25 (ADSCs-oe-SPC25-Exos), or a combination of both.
NP cells were then treated with psoralen, exosomes from adipose-derived stem cells overexpressing SPC25 (ADSCs-oe-SPC25-Exos), or a combination of both. Both individual treatments promoted cell proliferation and expression of aggrecan, COL2A1, Bcl-2, and CDK2, while reducing Bax, p16, p21 expression, and inflammatory factors, thereby inhibiting senescence, cycle arrest, and apoptosis. Notably, the combined treatment further decelerated NP cell senescence and cycle arrest compared to either agent alone, indicating a synergistic effect. The authors acknowledge that experiments were limited to the cellular level and that clinical sample numbers were limited, with animal experiments needed to confirm findings. The study has not yet been validated in vivo or in clinical settings.